Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812067 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Trial of TTHX1114 in People With CED
A Phase 2 study, sponsored by Trefoil Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04812067 is a Phase 2 study that has completed, run by Trefoil Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT04812067, a Phase 2 study, has completed, sponsored by Trefoil Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114
Interventions
- DRUG TTHX1114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04812067
The ClinicalTrials.gov registry entry for NCT04812067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trefoil Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TTHX1114 is the first listed.
NCT04812067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04812067 about?
NCT04812067 is a clinical study titled "A Safety and Efficacy Trial of TTHX1114 in People With CED". Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114
What is the current status of trial NCT04812067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-11-30. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04812067?
The interventions under investigation include: TTHX1114 (DRUG).
Who is sponsoring clinical trial NCT04812067?
This trial is sponsored by Trefoil Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.